Disclosed is the use of a pegylated interleukin 10 (PEG-IL-10) in the manufacture of a medicament for the treatment of a tumor, wherein the tumor is epithelial cell cancer, endothelial cell cancer, squamous cell carcinoma, papillomavirus-induced cancer, adenocarcinoma, carcinoma, melanoma, sarcoma or teratocarcinoma.